Systemic PEGylated TRAIL treatment ameliorates liver cirrhosis in rats by eliminating activated hepatic stellate cells

Yumin Oh, Ogyi Park, Magdalena Swierczewska, James P. Hamilton, Jong‐Sung Park, Tae Hyung Kim, Sung‐Mook Lim, Hana Eom, Dong Gyu Jo, Choong‐Eun Lee, Raouf Kechrid, Panagiotis Mastorakos, Clark Zhang, Sei Kwang Hahn, Ok‐Cheol Jeon, Youngro Byun, Kwangmeyung Kim, Justin Hanes, Kang Choon Lee, Martin G. Pomper, Bin Gao, Seulki Lee – 28 December 2015 – Liver fibrosis is a common outcome of chronic liver disease that leads to liver cirrhosis and hepatocellular carcinoma. No US Food and Drug Administration–approved targeted antifibrotic therapy exists.

Caspofungin versus fluconazole as prophylaxis of invasive fungal infection in high‐risk liver transplantation recipients: A propensity score analysis

Jesús Fortún, Alfonso Muriel, Pilar Martín‐Dávila, Miguel Montejo, Oscar Len, Julian Torre‐Cisneros, Jordi Carratalá, Patricia Muñoz, Maria Carmen Fariñas, Asunción Moreno, Gema Fresco, Josune Goikoetxea, Joan Gavaldá, Juan Carlos Pozo, Marta Bodro, Antonio Vena, Fernando Casafont, Carlos Cervera, José Tiago Silva, José M.

Genetic variation in STAT4 predicts response to interferon‐α therapy for hepatitis B e antigen‐positive chronic hepatitis B

De‐Ke Jiang, Xiaopan Wu, Ji Qian, Xiao‐Pin Ma, Jingmin Yang, Zhuo Li, Runhua Wang, Li Sun, Fang Liu, Pengyin Zhang, Xilin Zhu, Jia Wu, Kangmei Chen, Carly Conran, S. Lilly Zheng, Daru Lu, Long Yu, Ying Liu, Jianfeng Xu – 24 December 2015 – Interferon (IFN)‐α is a first‐line therapy for chronic hepatitis B (CHB) patients but only initiates a response in a minority of patients. A genetic variant, rs7574865 in STAT4, was recently reported to be associated with risk of developing CHB and hepatitis B virus‐related hepatocellular carcinoma.

Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A phase 3 study (OPTIMIST‐2)

Eric Lawitz, Gary Matusow, Edwin DeJesus, Eric M. Yoshida, Franco Felizarta, Reem Ghalib, Eliot Godofsky, Robert W. Herring, Gary Poleynard, Aasim Sheikh, Hillel Tobias, Marcelo Kugelmas, Ronald Kalmeijer, Monika Peeters, Oliver Lenz, Bart Fevery, Guy De La Rosa, Jane Scott, Rekha Sinha, James Witek – 24 December 2015 – Hepatitis C virus (HCV)–infected patients with cirrhosis are historically a difficult‐to‐treat population and are at risk of hepatic decompensation.

Subscribe to